Trials / Not Yet Recruiting
Not Yet RecruitingNCT07241260
Hydrate Heroes for Improving Brain Function & Mood
Boosting Brain and Mood: Exploring the Impact of Hydrate Heroes on Mental Health and Brain Activity
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- University of South Florida · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary goal of this 12-week randomized controlled study is to evaluate whether daily use of Hydrate Heroes results in measurable improvements in brain activity, mental health, and performance on cognitive tasks. By analyzing brainwave data, physical response metrics, and patient-reported outcomes, the study will demonstrate whether the supplement produces meaningful effects on mental and neurological health.
Detailed description
The study will utilize electrophysiological measurements of the brain and body. EEG recordings will be captured using the Emotiv FLEX 2.0 wireless headset, which measures brainwave activity across 32 electrode sites using a standard 10-10 system. EEG data will be collected at 256 Hz and analyzed using EEGLAB software to assess spectral power and topographic changes over time. The protocol includes 20 minutes of EEG testing per session, with specific tasks designed to elicit measurable cognitive responses. Participants will wear an Empatica Embrace wristband during testing to collect physiological data including motion, stress indicators, and heart rate variability. Participants will complete a series of validated tests on an iPad while wearing the EEG headset and wrist device. Tasks include: * Grandfather Passage (speech task) * Card Matching (memory and attention) * Boston Naming Test (language) * Finger Tapping (motor speed) * Trail Making Test (executive function) * Dual-Task Performance (cognitive load) Over 500 digital data features will be captured per session using a system that combines inputs from device sensors (e.g., gyroscope, camera, microphone) with user interactions (e.g., tapping, speech, app use). Participants will complete standardized questionnaires, including PROMIS-29+2 and IPAQ-SF, to assess aspects such as emotional well-being, physical activity, fatigue, and pain. The PROMIS-29+2 is aA collection of short forms or computer adaptive tests containing a fixed number of items from seven PROMIS domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities) The PROMIS-29+2 is used to calculate a preference score. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). Scores can be used in comparisons across groups and for cost-utility analyses. The profile includes all items in the PROMIS-29 Profile v2.1 plus two Cognitive Function Abilities items. T-scores from the measure can be used to calculate a preference-based score. International Physical Activity Questionnaire (IPAQ) short form is an 8-item questionnaire that encompasses time spent walking, in moderate and vigorous physical activity. The short form is feasible to administer and shows similar reliability and validity results in comparison to the long form. Test-rest reliability indicates good stability and high reliability (α \<.80). Scoring provides a categorization of low, moderate, or high intensity of physical activity. Ideally, this will be performed pre- and post-intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Hydrate Heroes (6 packets) | Participants that are randomized to the active comparator groups will receive 6 packets of Hydrate Heroes to use daily. |
| DIETARY_SUPPLEMENT | Hydrate Heroes (3 packets) | Participants that are randomized to the active comparator groups will receive 3 packets of Hydrate Heroes to use daily. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
- First posted
- 2025-11-21
- Last updated
- 2025-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07241260. Inclusion in this directory is not an endorsement.